1. Home
  2. NLSP vs MYNZ Comparison

NLSP vs MYNZ Comparison

Compare NLSP & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NLSP
  • MYNZ
  • Stock Information
  • Founded
  • NLSP 2015
  • MYNZ 2021
  • Country
  • NLSP Switzerland
  • MYNZ Germany
  • Employees
  • NLSP N/A
  • MYNZ N/A
  • Industry
  • NLSP Biotechnology: Pharmaceutical Preparations
  • MYNZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • NLSP Health Care
  • MYNZ Health Care
  • Exchange
  • NLSP Nasdaq
  • MYNZ Nasdaq
  • Market Cap
  • NLSP 8.2M
  • MYNZ 9.8M
  • IPO Year
  • NLSP 2021
  • MYNZ 2021
  • Fundamental
  • Price
  • NLSP $0.20
  • MYNZ $0.43
  • Analyst Decision
  • NLSP Hold
  • MYNZ Buy
  • Analyst Count
  • NLSP 1
  • MYNZ 2
  • Target Price
  • NLSP N/A
  • MYNZ $3.00
  • AVG Volume (30 Days)
  • NLSP 29.3M
  • MYNZ 1.3M
  • Earning Date
  • NLSP 07-30-2024
  • MYNZ 08-13-2024
  • Dividend Yield
  • NLSP N/A
  • MYNZ N/A
  • EPS Growth
  • NLSP N/A
  • MYNZ N/A
  • EPS
  • NLSP N/A
  • MYNZ N/A
  • Revenue
  • NLSP N/A
  • MYNZ $895,479.00
  • Revenue This Year
  • NLSP N/A
  • MYNZ $67.40
  • Revenue Next Year
  • NLSP N/A
  • MYNZ $191.13
  • P/E Ratio
  • NLSP N/A
  • MYNZ N/A
  • Revenue Growth
  • NLSP N/A
  • MYNZ 69.00
  • 52 Week Low
  • NLSP $0.11
  • MYNZ $0.32
  • 52 Week High
  • NLSP $1.21
  • MYNZ $4.79
  • Technical
  • Relative Strength Index (RSI)
  • NLSP 55.05
  • MYNZ 43.45
  • Support Level
  • NLSP $0.19
  • MYNZ $0.39
  • Resistance Level
  • NLSP $0.22
  • MYNZ $0.50
  • Average True Range (ATR)
  • NLSP 0.04
  • MYNZ 0.08
  • MACD
  • NLSP -0.00
  • MYNZ 0.01
  • Stochastic Oscillator
  • NLSP 17.96
  • MYNZ 46.04

About NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Share on Social Networks: